Multi-dose phase study of Dalfampridine in patients with post-stroke walking difficulty
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2016
At a glance
- Drugs Fampridine (Primary)
- Indications Stroke complications
- Focus Pharmacokinetics
- 22 Nov 2016 According to an Acorda Therapeutics media release, the company has decided to discontinue further development of dalfampridine for the treatment of post-stroke walking difficulties based on results of MILESTONE trial.
- 22 Nov 2016 According to an Acorda Therapeutics media release, status changed from planning to withdrawn prior to enrolment.
- 28 Jul 2016 Results from this trial are expected in the fourth quarter of 2016, according to an Acorda media release.